相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparison of efficacy and safety of intralesional triamcinolone and combination of triamcinolone with 5-fluorouracil in the treatment of keloids and hypertrophic scars: Randomised control trial
Farrukh Aslam Khalid et al.
BURNS (2019)
Improving the anti-keloid outcomes through liposomes loading paclitaxel-cholesterol complexes
Mengjiao Wang et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2019)
The Role of Fat Grafting in the Treatment of Keloid Scars and Venous Ulcers
Eva A. Williams et al.
JOURNAL OF CRANIOFACIAL SURGERY (2019)
Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma
Jong-Sung Park et al.
NATURE COMMUNICATIONS (2019)
Skin tissue regeneration for burn injury
Anastasia Shpichka et al.
STEM CELL RESEARCH & THERAPY (2019)
Patient-reported outcomes for keloids: a systematic review
Andrea Tan et al.
GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA (2019)
Intralesional Injection of Botulinum Toxin Type A Compared with Intralesional Injection of Corticosteroid for the Treatment of Hypertrophic Scar and Keloid: A Systematic Review and Meta-Analysis
Minglei Bi et al.
MEDICAL SCIENCE MONITOR (2019)
Targeting TRAIL
George Nicolae Daniel Ion et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Comparison of the efficacy of intralesional bleomycin versus intralesional triamcinolone acetonide in the treatment of keloids
Hina A. Khan et al.
DERMATOLOGIC THERAPY (2019)
The Interplay of Mechanical Stress, Strain, and Stiffness at the Keloid Periphery Correlates with Increased Caveolin-1/ROCK Signaling and Scar Progression
Teruyuki Dohi et al.
PLASTIC AND RECONSTRUCTIVE SURGERY (2019)
Molecular Mode of Action of TRAIL Receptor Agonists-Common Principles and Their Translational Exploitation
Harald Wajant
CANCERS (2019)
TRAIL-based gene delivery and therapeutic strategies
Hui-hai Zhong et al.
ACTA PHARMACOLOGICA SINICA (2019)
Understanding Keloid Pathobiology From a Quasi-Neoplastic Perspective: Less of a Scar and More of a Chronic Inflammatory Disease With Cancer-Like Tendencies
Silvian Tan et al.
FRONTIERS IN IMMUNOLOGY (2019)
Intralesional triamcinolone alone or in combination with botulinium toxin A is ineffective for the treatment of formed keloid scar: A double blind controlled pilot study
Sima Rasaii et al.
DERMATOLOGIC THERAPY (2019)
Integrated Interaction Network of MicroRNA Target Genes in Keloid Scarring
Lechun Lyu et al.
MOLECULAR DIAGNOSIS & THERAPY (2019)
Analysis of Keloid Response to 5-Fluorouracil Treatment and Long-Term Prevention of Keloid Recurrence
Ryan LaRanger et al.
PLASTIC AND RECONSTRUCTIVE SURGERY (2019)
Botulinum toxin type A for the treatment and prevention of hypertrophic scars and keloids: Updated review
Lorna Martin Kasyanju Carrero et al.
JOURNAL OF COSMETIC DERMATOLOGY (2019)
AMF siRNA treatment of keloid through inhibition signaling pathway of RhoA/ROCK1
Yi Tian et al.
GENES & DISEASES (2019)
Keloid treatment: what about adjuvant radiotherapy?
Ilias G. Petrou et al.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2019)
Advances in diagnostic methods for keloids and biomarker-targeted fluorescent probes
Sangrim Kang et al.
ANALYST (2019)
Characterization of CD45RO+ memory T lymphocytes in keloid disease
Z. Chen et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Three-dimensional poly lactic-co-glycolic acid scaffold containing autologous platelet-rich plasma supports keloid fibroblast growth and contributes to keloid formation in a nude mouse model
Chunlin Chen et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2018)
Identification of the potential targets for keloid and hypertrophic scar prevention
Lianbo Zhang et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
The role of TGF beta in wound healing pathologies
Dimitra Kiritsi et al.
MECHANISMS OF AGEING AND DEVELOPMENT (2018)
TRAIL-Dependent Resolution of Pulmonary Fibrosis
David M. Habiel et al.
MEDIATORS OF INFLAMMATION (2018)
Therapeutic significance of targeting survivin in cervical cancer and possibility of combination therapy with TRAIL
Hiroe Nakamura et al.
Oncotarget (2018)
The role and regulation of TMEM2 (transmembrane protein 2) in HYBID (hyaluronan (HA)-binding protein involved in HA depolymerization/KIAA1199/CEMIP)-mediated HA depolymerization in human skin fibroblasts
Yuta Yoshino et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Spontaneous Keloids: A Literature Review
Abdulhadi Jfri et al.
DERMATOLOGY (2018)
High in situ mRNA levels of IL-22, TFG-beta, and ARG-1 in keloid scars
Luciana Rodrigues da Cunha Colombo Tiveron et al.
IMMUNOBIOLOGY (2018)
TRAIL stabilization and cancer cell sensitization to its pro-apoptotic activity achieved through genetic fusion with arginine deiminase
Elena Brin et al.
Oncotarget (2018)
Detection and Analysis of the Hedgehog Signaling Pathway-Related Long Non-Coding RNA (IncRNAs) Expression Profiles in Keloid
Heping Huang et al.
MEDICAL SCIENCE MONITOR (2018)
TRAIL pathway targeting therapeutics
Marie D. Ralff et al.
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT (2018)
First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors
Andres Forero et al.
INVESTIGATIONAL NEW DRUGS (2017)
Current Understanding of the Genetic Causes of Keloid Formation
Donald A. Glass
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS (2017)
Soluble Extracellular Domain of Death Receptor 5 Inhibits TRAIL-Induced Apoptosis by Disrupting Receptor Receptor Interactions
Nagamani Vunnam et al.
JOURNAL OF MOLECULAR BIOLOGY (2017)
How Signaling Molecules Regulate Tumor Microenvironment: Parallels to Wound Repair
Peter Gal et al.
MOLECULES (2017)
From genetics to epigenetics: new insights into keloid scarring
Yongjing He et al.
CELL PROLIFERATION (2017)
Genetic association of the COL1A1 gene promoter-1997 G/T (rs1107946) and Sp1+1245 G/T (rs1800012) polymorphisms and keloid scars in a Jeddah population
Sahah A. Linjawi et al.
TURKISH JOURNAL OF MEDICAL SCIENCES (2016)
The molecular basis of hypertrophic scars
Zhensen Zhu et al.
BURNS & TRAUMA (2016)
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic NanobodyA® targeting the DR5 receptor
Kyriakos P. Papadopoulos et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Mechanism of Action, Efficacy, and Adverse Events of Calcium Antagonists in Hypertrophic Scars and Keloids: A Systematic Review
Svenna Verhiel et al.
DERMATOLOGIC SURGERY (2015)
Orphan nuclear receptor NR4A1 regulates transforming growth factor-β signaling and fibrosis
Katrin Palumbo-Zerr et al.
NATURE MEDICINE (2015)
TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells
M. H. Tuthill et al.
ONCOGENE (2015)
The use of chemotherapeutics for the treatment of keloid scars
Christopher David Jones et al.
DERMATOLOGY REPORTS (2015)
Rare genetic diseases, signalling pathways, and keloid scar formation
D. Lacombe et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Getting TRAIL back on track for cancer therapy
J. Lemke et al.
CELL DEATH AND DIFFERENTIATION (2014)
TRAIL+ NK Cells Control CD4+ T Cell Responses during Chronic Viral Infection to Limit Autoimmunity
Iona S. Schuster et al.
IMMUNITY (2014)
Associations between Keloid Severity and Single-Nucleotide Polymorphisms: Importance of rs8032158 as a Biomarker of Keloid Severity
Rei Ogawa et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Immunoglobulin Fc Domain Fusion to TRAIL Significantly Prolongs Its Plasma Half-Life and Enhances Its Antitumor Activity
Haizhen Wang et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion
Dimitra Peppa et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways
M. van Dijk et al.
CELL DEATH & DISEASE (2013)
Phase I Trial and Pharmacokinetic Study of Lexatumumab in Pediatric Patients With Solid Tumors
Melinda S. Merchant et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis
Emmet E. McGrath et al.
THORAX (2012)
The therapeutic potential of TRAIL receptor signalling in cancer cells
Rosario Yerbes et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2011)
TRAIL/DR5 Plays a Critical Role in NK Cell-Mediated Negative Regulation of Dendritic Cell Cross-Priming of T Cells
Mitsuhiro Iyori et al.
JOURNAL OF IMMUNOLOGY (2011)
Characterization of hyaluronan and TSG-6 in skin scarring: differential distribution in keloid scars, normal scars and unscarred skin
K. T. Tan et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2011)
Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)
Andres Forero-Torres et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2010)
A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
D. Ross Camidge et al.
CLINICAL CANCER RESEARCH (2010)
A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
Roy S. Herbst et al.
CLINICAL CANCER RESEARCH (2010)
Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Antitumor Activity and Tumor Targeting of NH2-Terminal-Specific PEGylated Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand
Su Young Chae et al.
MOLECULAR CANCER THERAPEUTICS (2010)
A genome-wide association study identifies four susceptibility loci for keloid in the Japanese population
Mitsuko Nakashima et al.
NATURE GENETICS (2010)
A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies
Sebastien J. Hotte et al.
CLINICAL CANCER RESEARCH (2008)
Genetic susceptibility to keloid scarring: SMAD gene SNP frequencies in Afro-Caribbeans
Jason J. Brown et al.
EXPERIMENTAL DERMATOLOGY (2008)
Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L
D. Berg et al.
CELL DEATH AND DIFFERENTIATION (2007)
Differential p63 and p53 expression in human keloid fibroblasts and hypertrophic scar fibroblasts
Bruna De Felice et al.
DNA AND CELL BIOLOGY (2007)
Targeted induction of apoptosis in cancer management: The emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents
EK Rowinsky
JOURNAL OF CLINICAL ONCOLOGY (2005)
分享论文
